SPRY ARS Pharmaceuticals PE ratio, current and historical analysis
The P/E ratio for ARS Pharmaceuticals stock stands at 163.13 as of Apr 2, 2025. The calculation is based on the latest EPS of $0.08 and the stock price of $13.05 per share.
SPRY PE ratio history
Over the last four years, the average PE ratio of ARS Pharmaceuticals has been 39.15. The current 163.13 price-to-earnings ratio is in line with the historical average. Analyzing the last four years, SPRY's PE ratio reached its highest point in the Dec 2024 quarter at 131.88, with a price of $10.55 and an EPS of $0.08. The Sep 2021 quarter saw the lowest point at 0.61, with a price of $9.98 and an EPS of $16.31.
ARS Pharmaceuticals PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 131.88 | N/A | $10.55 | $0.08 |
| 2023 | N/A | N/A | $5.48 | -$0.57 |
| 2022 | N/A | N/A | $8.53 | -$0.87 |
| 2021 | N/A | N/A | $6.66 | -$0.7 |
| 2020 | N/A | N/A | $46.34 | -$11.33 |
| 2019 | N/A | N/A | N/A | -$36.27 |
| 2018 | N/A | N/A | N/A | -$29.11 |
ARS Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | 131.88 | N/A | $10.55 | $0.08 |
| Sep 2024 | N/A | N/A | $14.5 | -$0.51 |
| Jun 2024 | N/A | N/A | $8.51 | -$0.47 |
| Mar 2024 | N/A | N/A | $10.22 | -$0.52 |
| Dec 2023 | N/A | N/A | $5.48 | -$0.57 |
| Sep 2023 | N/A | N/A | $3.78 | -$0.71 |
| Jun 2023 | N/A | N/A | $6.7 | -$0.76 |
| Mar 2023 | N/A | N/A | $6.51 | -$0.79 |
| Dec 2022 | N/A | N/A | $8.53 | -$0.87 |
| Sep 2022 | 9.96 | -78.86% | $5.28 | $0.53 |
| Jun 2022 | 47.11 | N/A | $4.24 | $0.09 |
| Mar 2022 | N/A | N/A | $3.51 | -$0.4 |
| Dec 2021 | N/A | N/A | $6.66 | -$0.7 |
| Sep 2021 | 0.61 | -90.15% | $9.98 | $16.31 |
| Jun 2021 | 6.19 | N/A | $30.89 | $4.99 |
SPRY average PE ratio chart
SPRY PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| SPRY ARS Pharmaceuticals Inc | 169 | $1.33B |
| OLMA Olema Pharmaceuticals Inc | N/A | $230.28M |
| OMER Omeros Corp | N/A | $432M |
| ONVO Organovo Holdings Inc | N/A | $3.16M |
| ORIC Oric Pharmaceuticals Inc | N/A | $370.76M |
| ORMP Oramed Pharmaceuticals Inc | N/A | $89.46M |
Frequently asked questions
What is ARS Pharmaceuticals's PE ratio?
SPRY stock has a price to earnings ratio of 163.13 as of Apr 2, 2025.
What is the highest PE ratio for SPRY?
Within the last four years, the current price to earnings ratio is at its peak with a value of 163.13.
How does the current PE ratio for SPRY compare to its historical average?
SPRY's current price to earnings ratio is 317% above its 4-year historical average.
Why is ARS Pharmaceuticals's PE ratio so high?
SPRY's PE ratio is high because the stock price is relatively expensive compared to the earnings generated by the company.
How is SPRY's PE ratio calculated (ARS Pharmaceuticals PE ratio formula)?
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (Apr 2, 2025), ARS Pharmaceuticals's share price is $13.05. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $0.08. Therefore, ARS Pharmaceuticals's price to earnings ratio for today is 163.13. PE RATIO(163.13) = STOCK PRICE($13.05) / TTM EPS($0.08)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.